About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT04429984

Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India

The main aim of this study is to measure the safety and to find out the effects of VPRIV in participants with Gaucher disease using both retrospective and prospective data when used in the post-market...

Lead sponsor: Shire•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Shire

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants with type 1 Gaucher disease prescribed VPRIV according to the investigator's judgment and current Indian Prescribing information (PI) are eligible for this study.
•Participants or legally authorized representative must provide written informed consent to participate.

Exclusion Criteria

•\- Participants will be excluded from this study if the participant met any of the contraindications included in the current Indian PI for VPRIV.

Related studies

RECRUITINGPhase 3

A Gaucher Disease Gene Therapy Trial With FLT201

NCT07223944 · Gaucher Disease Type 1

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

NCT05992532 · Gaucher Disease, Acid SphingoMyelinase Deficiency

Longitudinal Study of Neurodegenerative Disorders

NCT03333200 · MLD, Krabbe Disease, and more

Institutional Registry of Rare Diseases

NCT06573723 · Rare Diseases, Amyloidosis, and more

RECRUITINGPhase 1/2

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

NCT05487599 · Gaucher Disease, Gaucher Disease, Type 1

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 7, 2023Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment21

Start dateJul 2021

Last updatedJun 7, 2023

Condition

Gaucher Disease

Locations shown

Amrita Institute of Medical Sciences & Research Centre (AIMS)

Kochi, Kerala

All India Institute of Medical Sciences

New Delhi

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 7, 2023Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions